Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Empagliflozin with Closed-loop Insulin in Type 1 Diabetes
NCT04450563Phase 1Completed
- Sponsor
- McGill University
- Start
- Nov 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of empagliflozin in type 1 diabetes mellitus (T1D), sponsored by McGill University. Primary endpoint: Percentage of time of plasma glucose levels spent in target range (3.9 - 10.0 mmol/L) at 10 days. Started Nov 2020; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04450563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04450563.